These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31845436)

  • 1. Industry influence and Health Canada's responsibility: lessons from the opioid epidemic in Canada.
    Bavli I
    Addiction; 2020 Sep; 115(9):1605-1606. PubMed ID: 31845436
    [No Abstract]   [Full Text] [Related]  

  • 2. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Companies to pay $39.5m in OxyContin and Risperdal cases.
    McCarthy M
    BMJ; 2015 Dec; 351():h7018. PubMed ID: 26721284
    [No Abstract]   [Full Text] [Related]  

  • 4. The marketing of OxyContin®: A cautionary tale.
    Egilman DS; Collins GDYCB; Falender J; Shembo N; Keegan C; Tohan S
    Indian J Med Ethics; 2019; 4(3):183-193. PubMed ID: 31727614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canada's prescription opioid epidemic grows despite tamperproof pills.
    Dyer O
    BMJ; 2015 Sep; 351():h4725. PubMed ID: 26338104
    [No Abstract]   [Full Text] [Related]  

  • 6. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C.
    Powell D; Alpert A; Pacula RL
    Health Aff (Millwood); 2019 Feb; 38(2):287-294. PubMed ID: 30715966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid rain: opioid prescribing is growing and practice is diverging.
    Davis A; Davis K; Gerard C; Goyal S; Jackson G; James C; Loe E; Nicolls B; O'Rourke MA; Shuker C; Te Karu L
    N Z Med J; 2016 Aug; 129(1440):11-7. PubMed ID: 27538034
    [No Abstract]   [Full Text] [Related]  

  • 9. Kentucky seeks $1bn from Purdue Pharma for misrepresenting addictive potential of oxycodone.
    Dyer O
    BMJ; 2014 Nov; 349():g6605. PubMed ID: 25376623
    [No Abstract]   [Full Text] [Related]  

  • 10. Solving the Opioid Crisis: Respiratory Depression by Opioids as Critical End Point.
    Montandon G; Slutsky AS
    Chest; 2019 Oct; 156(4):653-658. PubMed ID: 31194974
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG; Coplan PM
    Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study.
    Fernandes K; Martins D; Juurlink D; Mamdani M; Paterson JM; Spooner L; Singh S; Gomes T
    PLoS One; 2016; 11(12):e0167479. PubMed ID: 27973601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticipating the effects of restricting high-dose preparations of strong opioids in Australia: A population-based analysis to inform the current policy debate.
    Zheng D; Narayan SW; Zoega H; Litchfield M; Buckley NA; Pearson SA; Schaffer AL
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):521-527. PubMed ID: 30790376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.
    Hays L; Kirsh KL; Passik SD
    J Natl Compr Canc Netw; 2003 Jul; 1(3):423-8. PubMed ID: 19761073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OxyContin abuse and overdose.
    Aquina CT; Marques-Baptista A; Bridgeman P; Merlin MA
    Postgrad Med; 2009 Mar; 121(2):163-7. PubMed ID: 19332974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
    J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth in Suicide Rates Among Children During the Illicit Opioid Crisis.
    Powell D
    Demography; 2023 Dec; 60(6):1843-1875. PubMed ID: 38009202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purdue Pharma to plead guilty and pay $8.3bn over opioid marketing.
    Dyer O
    BMJ; 2020 Oct; 371():m4103. PubMed ID: 33093019
    [No Abstract]   [Full Text] [Related]  

  • 20. A profile of OxyContin addiction.
    Hays LR
    J Addict Dis; 2004; 23(4):1-9. PubMed ID: 15339710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.